XML 81 R24.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders | 12 Months Ended
--- | ---
Dec. 31, 2018
Earnings Per Share [Abstract] |
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders | Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
The following table provides the detailed calculation of Earnings per common share (EPS):
|  | Year Ended December 31,
(IN MILLIONS) |  | 2018 |  |  | 2017 |  |  | 2016 |
EPS Numerator––Basic |  |  |  |  |  |  |
Income from continuing operations |  | $ | 11,179 |  |  | $ | 21,353 |  |  | $ | 7,229 |
Less: Net income attributable to noncontrolling interests |  | 36 |  |  | 47 |  |  | 31 |
Income from continuing operations attributable to Pfizer Inc. |  | 11,143 |  |  | 21,306 |  |  | 7,198 |
Less: Preferred stock dividends––net of tax |  | 1 |  |  | 1 |  |  | 1 |
Income from continuing operations attributable to Pfizer Inc. common shareholders |  | 11,142 |  |  | 21,305 |  |  | 7,197 |
Discontinued operations––net of tax |  | 10 |  |  | 2 |  |  | 17 |
Less: Discontinued operations––net of tax, attributable to noncontrolling interests |  | — |  |  | — |  |  | — |
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders |  | 10 |  |  | 2 |  |  | 17 |
Net income attributable to Pfizer Inc. common shareholders |  | $ | 11,152 |  |  | $ | 21,307 |  |  | $ | 7,214 |
EPS Numerator––Diluted |  |  |  |  |  |  |  |
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions |  | $ | 11,143 |  |  | $ | 21,306 |  |  | $ | 7,197 |
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions |  | 10 |  |  | 2 |  |  | 17 |
Net income attributable to Pfizer Inc. common shareholders and assumed conversions |  | $ | 11,153 |  |  | $ | 21,308 |  |  | $ | 7,214 |
EPS Denominator |  |  |  |  |  |  |  |
Weighted-average number of common shares outstanding––Basic(a) |  | 5,872 |  |  | 5,970 |  |  | 6,089 |
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements(a) |  | 105 |  |  | 89 |  |  | 70 |
Weighted-average number of common shares outstanding––Diluted |  | 5,977 |  |  | 6,058 |  |  | 6,159 |
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans(b) |  | 2 |  |  | 36 |  |  | 63 |
Cash dividends declared per share |  | $ | 1.38 |  |  | $ | 1.30 |  |  | $ | 1.22 |
(a) | 2017 includes the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.
(b) | These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration